Calcitonin Gene-related Peptide Levels in Chronic Migraine
Status:
Completed
Trial end date:
2011-06-01
Target enrollment:
Participant gender:
Summary
Twenty patients will be enrolled in a 2-site, 7-month, double-blind study conducted to
evaluate a reduction in headache days and attacks and calcitonin gene-related peptide (CGRP)
levels in saliva following treatment with OnabotulinumtoxinA versus saline.
Eligible patients will be randomized and receive injections of OnabotulinumtoxinA or Saline
at Visit 1. Following 3 months plus a 1 month wash out, patients will receive cross-over
injections at Visit 5.
Patients will return for monthly visits and exit the study at Visit 8.
Patients will collect saliva at monthly intervals and document in a daily headache diary
throughout the study .
Phase:
Phase 4
Details
Lead Sponsor:
Cady, Roger, M.D.
Collaborator:
Allergan
Treatments:
abobotulinumtoxinA Botulinum Toxins Botulinum Toxins, Type A Calcitonin Calcitonin Gene-Related Peptide incobotulinumtoxinA onabotulinumtoxinA Salmon calcitonin